Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Radiation Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1507806

Clinical feasibility of Ethos auto-segmentation for adaptive wholebreast cancer treatment

Provisionally accepted
Jessica Prunaretty Jessica Prunaretty *Fatima Mekki Fatima Mekki Pierre-Ivan Laurent Pierre-Ivan Laurent Aurelie Morel Aurelie Morel Pauline Hinault Pauline Hinault Celine Bourgier Celine Bourgier David AZRIA David AZRIA *Pascal Fenoglietto Pascal Fenoglietto
  • Institut du Cancer de Montpellier (ICM), Montpellier, France

The final, formatted version of the article will be published soon.

    Introduction : To clinically evaluate the automatic segmentation generated by Ethos. Material and Methods: Twenty patients initially treated for different breast cancer indications were replanned using the EthosĀ® emulator.The adaptive workflow was performed using 5 randomly selected extended CBCTs per patient. The contours generated by artificial intelligence (AI) included both breasts, the heart, and the lungs. The target volumes, specifically the tumor bed (CTV_Boost), internal mammary chain (CTV_IMC), and clavicular nodes (CTV_Nodes), were generated through rigid propagation. The CTV_Breast corresponds to the ipsilateral breast, excluding 5mm from the skin. Two radiation oncologists independently repeated the workflow and qualitatively assessed the accuracy of the contours using a scoring system from 3 (contour to be redone) to 0 (no correction needed). Quantitative evaluation was carried out using the Dice Similarity Coefficient (DSC), Hausdorff Distance (HD), surface Dice (sDSC) and the Added Path Length (APL). The interobserver variability (IOV) between the two observers was also assessed and served as a reference. Lastly, the dosimetric impact of contour correction was evaluated. The physician-validated contours were transferred onto the plans automatically generated by Ethos in adaptive mode. The CTV/PTV margin was 2mm for all volumes, except for the IMC (5mm). Dose coverage (D98%) was assessed for the CTVs, while specific parameters for organs at risk (OAR) were evaluated: mean dose and V17Gy (relative volume receiving at least 17Gy) for the ipsilateral lung, mean dose and D2cc (dose received by 2cc volume) for the heart, the contralateral lung and breast.Results: The qualitative analysis showed that no correction or only minor corrections were needed for 98.6% of AI-generated contours and 86.7% of the target volumes. Regarding the quantitative analysis, Ethos' contour generation outperformed inter-observer variability for all structures in terms of DSC, HD, sDSC and APL. Target volume coverage was achieved for 97.9%, 96.3%, 94.2% and 68.8% of the breast, IMC, nodes and boost CTVs, respectively. As for OARs, no significant differences in dosimetric parameters were observed.This study shows high accuracy of segmentation performed by Ethos for breast cancer, except for the CTV_Boost. Contouring practices for adaptive sessions were revised following this study to improve outcomes.

    Keywords: ethos, Auto-segmentation, artificial intelligence, breast cancer, Adaptive treatment

    Received: 08 Oct 2024; Accepted: 21 Nov 2024.

    Copyright: Ā© 2024 Prunaretty, Mekki, Laurent, Morel, Hinault, Bourgier, AZRIA and Fenoglietto. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Jessica Prunaretty, Institut du Cancer de Montpellier (ICM), Montpellier, France
    David AZRIA, Institut du Cancer de Montpellier (ICM), Montpellier, France

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.